Indication and Usage

Daily administration of Pulmozyme^® (dornase alfa) Inhalation Solution along with standard therapies is indicated in the management of cystic fibrosis patients to improve lung function. In patients with a forced vital capacity (volume of air exhaled with maximum effort and speed) greater than or equal to 40% of predicted, daily administration of Pulmozyme has also been shown to reduce the risk of respiratory tract infections requiring the administration of injectable antibiotics. In our pivotal study, safety and efficacy of daily administration has not been studied in patients beyond 12 months.

Important Safety Information

• Pulmozyme should not be used in patients who are allergic to any of its ingredients

• Pulmozyme should be used along with standard therapies for cystic fibrosis

• When starting Pulmozyme therapy, patients may experience change in or loss of their voice, discomfort in the throat, chest pain, red watery eyes, rash, dizziness, fever, or runny nose

• These side effects are usually mild and short-lived

• The effect of Pulmozyme on exercise tolerance has not been established in adults and children

For further information, please see the Pulmozyme full prescribing information. If you have questions, please discuss them with your CF healthcare team.